TY - JOUR T1 - Spatial Accessibility Modeling of Vaccine Deserts as Barriers to Controlling SARS-CoV-2 JF - medRxiv DO - 10.1101/2021.06.09.21252858 SP - 2021.06.09.21252858 AU - Benjamin Rader AU - Christina M. Astley AU - Kara Sewalk AU - Paul L. Delamater AU - Kathryn Cordiano AU - Laura Wronski AU - Jessica Malaty Rivera AU - Kai Hallberg AU - Megan F. Pera AU - Jonathan Cantor AU - Christopher M. Whaley AU - Dena M. Bravata AU - John S. Brownstein Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/12/2021.06.09.21252858.abstract N2 - SARS-CoV-2 vaccine distribution is at risk of further propagating the inequities of COVID-19, which in the United States (US) has disproportionately impacted the elderly, people of color, and the medically vulnerable. We identify vaccine deserts - US Census tracts with localized, geographic barriers to vaccine-associated herd immunity - using a comprehensive supply database (VaccineFinder) and an empirically parameterized model of spatial access to essential resources. Incorporating high-resolution COVID-19 burden and time-willing-to-travel for vaccination, we show that early (February – March 2021) vaccine allocation disadvantaged rural and medically vulnerable populations. Data-driven vaccine distribution to vaccine deserts may improve immunization in the hesitant and control SARS-CoV-2.Competing Interest StatementJSB reports that VaccineFinder.org has received programmatic funding from the U.S. Centers for Disease Control and Prevention.Funding StatementThis work was supported by Flu Lab and Ending Pandemics. BR, CMA and JSB acknowledge funding from Facebook Sponsored Research Agreement [INB1116217]. BR and JSB acknowledge funding from Google.org via the Tides Foundation [TF2003-089662].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ONM survey was approved by the Boston Children's Hospital Institutional Review Board (IRB-P00023700) and received a waiver of informed consent. The Delphi Group survey protocol was approved by the Carnegie Mellon University IRB (STUDY2020_00000162).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReal-time vaccine site location is available at VaccineFinder.org for locations that choose to publicly display. Raw data is not available for sharing. Delphi Group Facebook COVID-19 Symptom Survey data may requested via [https://cmu-delphi.github.io/delphi-epidata/]. ER -